1 A novel muscarinic receptor antagonist, solifenacin succinate, inhibited specific binding of [N-methyl-3 H]-scopolamine ([ 3 H]-NMS) in the mouse bladder, submaxillary gland and heart in a concentration-dependent manner. This inhibitory effect was greatest in the submaxillary gland, followed by the bladder and heart. 2 After oral administration of oxybutynin (76.1 mmol kg 3 H]-NMS binding was seen in the bladder, prostate, submaxillary gland, heart, colon and lung, compared with control values. The increase in K D induced by oxybutynin in each tissue reached a maximum 0.5 h after oral administration and then rapidly declined, while that induced by solifenacin was greatest 2 h after administration and was maintained for at least 6 or 12 h, depending on the dose. The muscarinic receptor binding of oral solifenacin was slower in onset and of a longer duration than that of oxybutynin. 3 Plasma concentrations of oxybutynin and its active metabolite (N-desethyl-oxybutynin, DEOB) were maximum 0.5 h after its oral administration and then declined rapidly. Oral solifenacin persisted in the blood for longer than oxybutynin. 4 Pilocarpine-induced salivary secretion in mice was significantly reduced by oral administration of solifenacin and was completely abolished 0.5 h after oral oxybutynin. Although the suppression induced by solifenacin was more persistent than that due to oxybutynin, the antagonistic effect of solifenacin on the dose-response curves to pilocarpine was significantly weaker than that of oxybutynin. It is concluded that oral solifenacin persistently binds to muscarinic receptors in tissues expressing the M 3 subtype, such as the bladder.
Introduction
An overactive bladder is characterized by symptoms of increased frequency of micturition, urgency and urge incontinence (Bulmer & Abrams, 2000; Abrams et al., 2002) . Muscarinic receptor antagonists such as oxybutynin have been used for some time to treat overactive bladder (Andersson, 1988; Wein, 1990) . However, the oral use of oxybutynin is often limited by frequent and serious systemic side effects such as dry mouth, blurred vision, constipation and tachycardia (Yarker et al., 1995) . To reduce or even eliminate this problem, novel antimuscarinic agents that exhibit pharmacological selectivity in the bladder relative to other tissues such as the salivary gland have been developed (Nilvebrant et al., 1997; Abrams et al., 1998; Anderson et al., 1999; Gupta & Sathyan, 1999; Chapple, 2000) .
Muscarinic cholinoceptors have been classified into five subtypes (M 1 -M 5 ) based on genetic and pharmacological characteristics (Hulme et al., 1990; Caulfield, 1993) . Although both M 2 and M 3 subtypes coexist in smooth muscle, the M 2 subtype predominates but functional in vitro data with a number of selective antagonists indicate that the contraction of most smooth muscle, including the urinary bladder, is mediated by the M 3 subtype (Caulfield, 1993; Eglen et al., 1994) . On the basis of these results, muscarinic receptor antagonists with a higher affinity for M 3 than M 2 subtypes should be more beneficial in the treatment of overactive bladder.
Solifenacine succinate (YM905; [( þ )-(1S,3 0 R)-quinuclidin-3 0 -yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate]) is a novel muscarinic receptor antagonist developed for the treatment of urinary incontinence and other symptoms of overactive bladder (Ikeda et al., 2002; Kobayashi et al., 2004) . In vitro radioligand studies with human recombinant muscarinic subtypes have revealed that solifenacin exhibits high affinity and specificity for the muscarinic M 3 subtype relative to the M 1 and M 2 subtypes; the affinity of solifenacin for these subtypes is 6-10 times less than that of oxybutynin (Ikeda et al., 2002) . Solifenacin has been found to be equipotent with oxybutynin at inhibiting carbachol-stimulated Ca 2 þ mobilization in detrusor cells, but less potent in submandibular gland cells (Ikeda et al., 2002; Kobayashi et al., 2004) . In vivo studies in anaesthetized rats have shown that solifenacin, unlike oxybutynin, is more potent at inhibiting bladder contraction than salivation (Ikeda et al., 2002; Ohtake et al., 2004) .
A number of authors have indicated the importance of characterizing the binding of ligands to receptors in the presence of various pharmacokinetic and pharmacodynamic factors (Beauchamp et al., 1995; Uchida et al., 1995; Ohkura et al., 1998; Yamada et al., 2001; . The aim of the present study was to characterize the in vivo muscarinic receptor binding properties of solifenacin (after oral administration) in the bladder and submaxillary gland, compare them with those of oxybutynin and relate them to their plasma levels and inhibitory effects on salivary secretion.
Methods

Animals
Male ddY strain mice aged 11 to 16 weeks (Japan SLC Inc., Shizuoka, Japan) were used. They were housed under a 12-h light-dark cycle and fed laboratory chow and water ad libitum.
Administration of oxybutynin and solifenacin
Mice were fasted for 16 h, then orally administered oxybutynin (76.1 mmol kg
À1
) or solifenacin (62.4 or 208 mmol kg À1 ) dissolved in distilled water. Control animals received vehicle alone. The study was conducted in accordance with the guidelines of the Experimental Animal Ethical Committee of the University of Shizuoka.
Tissue preparation
At 0.5 to 24 h after drug administration, the mice were anaesthetized with diethyl ether and exsanguinated by taking the blood from the descending aorta. The tissues were then perfused with cold saline via the aorta. The bladder, prostate, submaxillary gland, heart, lung and colon were dissected out, and any fat and blood vessels removed. As the individual organs did not weigh very much, samples from three mice were pooled for a determination of the results. The tissues were minced with scissors and homogenized with a Kinematica Polytron homogenizer in 19 volumes of ice-cold 30 mM Na þ /HEPES buffer (pH 7.5). The homogenates were then centrifuged at 40,000 Â g for 20 min and the resulting pellet was suspended in ice-cold buffer for the binding assay. In the ex vivo experiments, it is possible that oxybutynin and solifenacin can dissociate from the receptor sites during tissue preparation (homogenization and suspension). Yamada et al. (1980) have shown that such dissociation is extremely slow at 41C, hence all preparation was conducted at this temperature. Protein concentrations were measured according to the method of Lowry et al. (1951) . Mouse plasma was isolated from blood by centrifugation and stored at À801C until analysis.
Muscarinic receptor binding assay
The binding assay for muscarinic receptors was performed using [N-methyl-3 H]-scopolamine methyl chloride ([ 3 H]-NMS) as previously described (Ehlert & Tran, 1990; Oki et al., 2004) . The mouse tissue homogenates (60-860 mg protein) were incubated with different concentrations (0.06-1.0 nM) of [ 3 H]-NMS in 30 mM Na þ /HEPES buffer (pH 7.5) for 60 min at 251C. The reaction was terminated by rapid filtration (Cell Harvester, Brandel Co., Gaithersburg, MD, U.S.A.) through Whatman GF/B glass fibre filters, and the filters were then rinsed three times with 3 ml of ice-cold buffer. Tissue-bound radioactivity was extracted from the filters by overnight immersion in scintillation fluid (2 1 toluene, 1 1 Triton X-100, 15 g 2,5-diphenyloxazole, 0.3 g 1,4-bis[2-(5-phenyloxazolyl)]benzene), and radioactivity was determined with a liquid scintillation counter. Specific [ 3 H]-NMS binding was determined as the difference between counts in the absence and presence of 1 mM atropine. All assays were performed in duplicate.
Measurement of plasma concentrations
Concentrations of oxybutynin and its active metabolite (Ndesethyl-oxybutynin: DEOB) in mouse plasma were determined by gas chromatography and mass spectrometry (GC/ MS) as described previously (Oki et al., 2004) . A plasma sample (0.1-0.5 ml) was mixed with internal standard ([ 2 H 13 ]-oxybutynin . HCl and [ 2 H 13 ]-DEOB . HCl) and, after alkalinization with 0.5 ml of 0.5 M carbonate buffer (pH 9.5), extracted with 6 ml of n-hexane. After centrifugation at 1500 Â g for 5 min, the supernatant was evaporated to dryness under reduced pressure. The residue was dissolved in 100 ml of CH 3 CN, and 0.5-1 ml was injected into a GC/MS system consisting of a 5890 Series II gas chromatograph, a 5792 Series mass selective detector, a 7673 GC/SFC injector, a VECTRA 486/66U computer and a LaserJet 4 printer (Hewlett Packard Co.). Chromatographic separation was carried out using a 15 m Â 0.25 mm i.d. Â 0.25 mm film UA þ -1 HT (Frontier Lab Ltd.). The carrier gas was helium at a flow rate of 1.0 ml min À1 . Oven temperature was held at 1501C for 1 min, then programmed from 150 to 2201C at 201C min À1 for the first ramp, from 220 to 2601C at 101C min À1 for the second ramp, and from 260 to 3001C at 301C min À1 for the third ramp. It was held at 3001C for 2 min and then returned to the initial starting temperature of 1501C. The concentration of solifenacin in mouse plasma was determined by a validated high-performance liquid chromatographic (HPLC) method. Briefly, solifenacin was extracted from mouse plasma by a two-step liquid-liquid extraction and analysed by semi-micro HPLC with UV detection. The lower limit of detection was 20.8 nM.
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Measurement of salivary secretion
Mice were anaesthetized with pentobarbitone (161 mmol kg
À1
, intraperitoneally (i.p.)). Any saliva remaining in the oral cavity was removed with a cotton ball before measuring the total saliva collected in the cavity for a 10-min period. The saliva was absorbed onto three to five cotton balls for 10 min and the balls were weighed on an electric balance immediately after the collection period to prevent moisture loss. To examine the effects of oral administration of oxybutynin and solifenacin on pilocarpine-induced salivary secretion, pilocarpine (4.09 mmol kg
, dissolved in physiological saline) was administered (intravenous, i.v.) 0.5, 2, 6, 12 and 24 h after oral administration of the drugs, and saliva was collected for 10 min. The effect of oral administration of oxybutynin and solifenacin on total salivary secretion induced by cumulative doses (0.41-40.9 mmol kg À1 , i.v.) of pilocarpine given at 5-min intervals was also measured.
Data analysis
Analysis of [
3 H]-NMS binding data was performed as described previously (Yamada et al., 1980 For the analysis of salivary secretion data, pK B values were calculated using the equation pK B ¼ log (CRÀ1)Àlog [antagonist] , where CR is the ratio of ED 50 values (the dose producing 50% of the maximum response) of the agonist with and without antagonist (van Rossum et al., 1963) .
Statistical analysis of the data was performed by one-way analysis of variance (ANOVA) followed by Dunnett's test for multiple comparisons. A value of Po0.05 was considered significant. ) was purchased from PerkinElmer Life Sciences, Inc. (Boston, MA, U.S.A.). Solifenacin succinate (YM905) was donated by Yamanouchi Pharmaceutical Co. Ltd (Tsukuba, Japan). Oxybutynin hydrochloride and its active metabolite (DEOB) were donated by Meiji Milk Products Co. Ltd (Odawara, Japan). All other chemicals were purchased from commercial sources.
Materials
Results
In vitro effects of oxybutynin, DEOB and solifenacin on muscarinic receptors in mouse tissues
Oxybutynin (1-1000 nM) and DEOB (0.3-100 nM) inhibited specific [
3 H]-NMS binding in the bladder, submaxillary gland and heart in a concentration-dependent manner in vitro.
Respective pK i values for oxybutynin in these tissues were 7.80, 8.22 and 7.39, while those for DEOB were 8.30, 9.00 and 7.80 (Table 1 ). The inhibitory potencies for DEOB in the bladder, submaxillary gland and heart were thus significantly (Po0.01) higher (3.1, 6.0 and 2.6 times, respectively) than those obtained for oxybutynin. Solifenacin (3-1000 nM) inhibited specific [ 3 H]-NMS binding in the bladder, submaxillary gland and heart, and the associated pK i values were 7.38, 7.89 and 7.00, respectively (Table 1 ). The inhibitory effect of solifenacin was significantly lower (1/3.2) in the submaxillary gland and higher (2.4 times) in the heart than in the bladder. Further, the inhibitory effects of solifenacin in the bladder, submaxillary gland and heart were significantly lower (1/2.6, 1/2.1 and 1/2.4 respectively) than those of oxybutynin.
The Hill slopes for oxybutynin, DEOB and solifenacin in these tissues were close to unity except that for DEOB in the submaxillary gland which was 0.78.
Effects of oral administration of oxybutynin and solifenacin on muscarinic receptors in mouse tissues
At 0.5 and/or 2 h after oral administration of oxybutynin (76.1 mmol kg À1 ), there was a significant increase in the K D value for specific [ 3 H]-NMS binding in the bladder, prostate, submaxillary gland, heart, lung and colon compared with the corresponding control values ( Table 2 ). The increases were maximal after 0.5 h being 54.5, 220, 668, 91.7, 391 and 269%, respectively, while those at 2 h were 44.3, 218, 215, 16.9, 115 and 109%, respectively. The increase at 0.5 h was least in the bladder and most in the submaxillary gland. The K D in each tissue was not significantly different from the control value at 6, 12 and 24 h. Oxybutynin had no significant effect on B max values for specific (Table 3) . These effects were significant in the heart (24.0 and 25.1%) and lung (244 and 182%) at 0.5 and 2 h, in the bladder (18.2-29.0%) and submaxillary gland (106-363%) at 0.5 to 6 h, and in the prostate (72.7-120%) and colon (83.6-85.6%) at 0.5 to 12 h. In addition, the maximum effect in each (Table 4) , with increases being significant in the heart (56.5 and 47.0%, respectively) at 0.5 and 2 h, and in the bladder (22.2-49.4%), prostate (166-320%), submaxillary gland (234-613%) and colon (116-131%) at 0.5 to 12 h. Solifenacin had no significant effect on the B max value for any of the tissues, except in the heart where a significant (38.1%) increase occurred at 2 h (at the dose of 208 mmol kg À1 ).
Plasma levels of oxybutynin, DEOB and solifenacin Figure 1 shows the plasma concentrations of oxybutynin, DEOB and solifenacin over time after oral administration of oxybutynin and solifenacin. The concentrations of oxybutynin and DEOB reached maximum levels (oxybutynin, 91.5734.3 nM; DEOB, 75.8720.6 nM; n ¼ 7-9) 0.5 h after administration of oxybutynin (76.1 mmol kg
À1
) and then they rapidly declined (Figure 1a) . Respective plasma concentrations of oxybutynin at 2 and 6 h were 16.372.7 and 3.1571.54 nM, while those of DEOB were 28.875.3 and 2.1872.18 nM. Solifenacin at doses of 62.4 and 208 mmol kg À1 produced dose-dependent increases in its plasma concentration. Maximum levels were reached at 0.5 h (8867176 nM; n ¼ 6) and 2 h (13817201 nM; n ¼ 6), respectively, followed by a gradual decline (Figure 1b) to 546784, 178720, 127729 and 38.5 nM at 2, 6, 12 and 24 h, respectively, and to 8047233, 283740 and 38.776 .0 nM at 6, 12 and 24 h, respectively. Figure 2 shows the effect of oral administration of oxybutynin and solifenacin on pilocarpine-induced salivary secretion in mice. Salivary secretion induced by an i.v. injection of pilocarpine in control mice showed good reproducibility, with similar amounts of saliva being secreted during the 10-min collection period at 0.5, 2, 6, 12 and 24 h after stimulation (293718, 263714, 22879, 234715 and 25279 mg, respectively (n ¼ 12)). Pilocarpine-induced secretion was significantly decreased at 0.5 and 2 h after oral administration of oxybutynin (76.1 mmol kg À1 ), compared with the control value; the response to pilocarpine was almost abolished at 0.5 h but secretion recovered to the control level at 6 h.
Salivary secretion
Similarly, pilocarpine-induced salivary secretion was markedly reduced but not abolished at 0.5-6 h after oral administration of solifenacin (62.4 and 208 mmol kg À1 ), as shown by residual saliva (62.4 mmol kg
À1
: 0.5 h, 66.0720.4 mg; 2 h, 54.6723.3 mg; 6 h, 75.2719.6 mg; and 208 mmol kg À1 : 0.5 h, 36.6720.8 mg; 2 h, 11.872.3 mg; 6 h, 44.2715.6 mg). There was little difference in the secretion responses between the control and solifenacin treatment groups at 12 and 24 h.
As shown in Figure 3 , cumulative doses of pilocarpine (0.41-40.9 mmol kg À1 , i.v.) induced dose-dependent salivary secretion. To determine the effects of oxybutynin and solifenacin on these dose-response curves, secretion was measured at the time of maximum inhibition of pilocarpineinduced salivation, that is 0.5 h for oxybutynin and 2 h for solifenacin (Figure 2 ). Both oxybutynin (76.1 mmol kg À1 ) and solifenacin (62.4, 208 mmol kg À1 ) caused a rightward shift in the dose-response curve for pilocarpine-induced salivation, but the inhibitory effect of solifenacin, 62.4 mmol kg
, was significantly weaker than that of oxybutynin (76.1 mmol kg À1 ). 
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Thus, the pK B value for oxybutynin (5.5370.03) was significantly greater (Po0.001) than that for solifenacin (4.8570.05).
Discussion
The usefulness of ex vivo and in vivo receptor binding assays in predicting the potency, organ selectivity and duration of action of drugs in relation to their pharmacokinetic and pharmacodynamic profiles is well documented (Beauchamp et al., 1995; Uchida et al., 1995; Ohkura et al., 1998; Yamada et al., 2001; . In the present study, the in vivo muscarinic receptor binding of solifenacin was characterized and compared to that of oxybutynin by simultaneously measuring [ 3 H]-NMS binding in various tissues, including the bladder and submaxillary gland. Also their plasma concentrations and effects on salivary secretion after oral administration were compared. The doses of solifenacin given (2.1-208 mmol kg À1 ) were similar to those shown to have an inhibitory effect in experimental models of bowel dysfunction in vivo (Kobayashi et al., 2001) .
It is known that the heart and salivary gland contain predominantly M 2 and M 3 muscarinic subtypes, respectively (Giraldo et al., 1988; Caulfield, 1993) , whereas the bladder contains both, with the M 2 dominating over the M 3 subtype (Wang et al., 1995) . Furthermore, functional and binding studies have shown that, although M 3 -receptors are the main contributors, M 1 , M 4 and M 5 receptor subtypes may also have a role in muscarinic agonist-induced salivation in mice (Hammer et al., 1980; Yeomans et al., 2001; Takeuchi et al., 2002; Bymaster et al., 2003; Gautam et al., 2004; Nakamura et al., 2004) . In the present in vitro experiments, both solifenacin and oxybutynin competed with [ 3 H]-NMS for binding sites in the bladder, submaxillary gland and heart of mice in a concentration-dependent manner. The pK i values indicated that the muscarinic receptor binding affinity of solifenacin in these tissues was 2-3 times weaker than that of oxybutynin. Ikeda et al. (2002) have previously found that the pK i values of solifenacin for M 1 , M 2 and M 3 subtypes in binding assays were 7.6, 6.9 and 8.0, respectively. Thus, pK i values of this agent in the mouse heart and submaxillary gland (7.0 and 7.89; Table 1 ) agree well with the respective M 2 and M 3 values, while in the bladder the pK i (7.4) was intermediate between these two subtypes. A similar correlation in relative affinity between recombinant receptor subtypes and native tissues has been observed for oxybutynin (Ikeda et al., 2002) .
After oral administration of solifenacin (62.4, 208 mmol kg À1 ) and oxybutynin (76.1 mmol kg À1 ), dose-and time-dependent increases in K D values for specific [ 3 H]-NMS binding were seen in the bladder, prostate, submaxillary gland, heart, colon and lung of mice, with little effect on B max values. Given that an increase in K D values for radioligands in drug-pretreated tissues in this type of assay usually indicates competition between the agent and radioligand for the same binding sites (Ohkura et al., 1998; Yamada et al., 2003) , these data strongly suggest that orally administered solifenacin and oxybutynin undergo significant binding to muscarinic receptors in these tissues. Differences were seen between the two drugs in the time course of their effects on the K D values for [ 3 H]-NMS binding. With oxybutynin, the increase in K D in each tissue reached a maximum 0.5 h after oral administration, followed by a rapid decline. In contrast, the increase in K D with solifenacin in most tissues was greatest at 2 h and was maintained for up to 6 or 12 h, depending on dose; its effect was slower in onset and longer in duration compared to that of oxybutynin. This apparent difference between solifenacin and oxybutynin appears to depend largely on their rate of increase and disappearance in the plasma. The plasma concentration of oxybutynin reached a maximum 0.5 h after oral administration and then declined rapidly, whereas 
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Muscarinic receptor binding of oral solifenacin that of solifenacin peaked at 0.5 or 2 h and then declined more slowly. Based on the intensity and duration of the increases in K D values, the muscarinic receptor binding activity of solifenacin is greatest in the submaxillary gland and lowest in the heart and persistent in the bladder, prostate, submaxillary gland and colon but transient in the heart and lung. Recent data with M 1 -M 5 subtype knockout mice show that the M 3 subtype is expressed predominantly (70-80%) in the submaxillary gland and moderately in the prostate and bladder, whereas M 2 is the main subtype present in the bladder, heart, lung and colon (Oki et al., unpublished observation) . The tissue selectivity of oral solifenacin may therefore reflect the muscarinic subtype selectivity shown in the in vitro assay (Ikeda et al., 2002 , Table 1 ). Consequently, it is possible that the higher affinity of solifenacin for the M 3 compared to the M 2 subtype accounts for its persistent binding to muscarinic receptors in the mouse bladder, prostate and submaxillary gland and transient binding in M 2 -predominant tissues. As mouse salivary gland has recently been shown to contain functional M 1 , M 4 and M 5 -receptor subtypes, the partial binding of solifenacin to these non-M 3 -receptor subtypes cannot be ruled out. Moreover, it should be noted that NMS itself displays higher affinity for the M 3 than M 2 subtype (Waelbroeck et al., 1990) . The persistent binding of solifenacin in the mouse colon remains to be clarified. It is possible that solifenacin, similar to the long-lasting 1,4-dihydropyridine calcium channel antagonists, benidipine and amlodipine has slower receptor binding kinetics of association and dissociation. In our preliminary experiments in vitro, no significant difference was observed between solifenacin and oxybutynin in their association rates of muscarinic receptor binding in the submaxillary gland and heart. Solifenacin was more readily dissociated from muscarinic receptors in the submaxillary gland compared with the heart, while the dissociation rate of oxybutynin was similar in both tissues. These data do not appear to support the results obtained ex vivo after oral administration of these agents (Tables 2-4) . However, kinetic data obtained from in vitro studies may not necessarily reflect receptor binding kinetics under in vivo conditions, which could be greatly influenced by various pharmacokinetic factors, regional blood flow and intrinsic cholinergic neuronal activity in each tissue. A comparative kinetic analysis of drug concentration and muscarinic receptor binding in tissues of mice administered radiolabelled forms of solifenacin and oxybutynin might clarify any differences in the in vivo binding characteristics of these agents and also between tissues.
Recently, in contrast to our results, Nelson et al. (2004) found that oxybutynin selectively inhibits carbacholstimulated phosphoinositide responses in slices of bladder from the guinea-pig when compared to the submandibular gland. Our finding, in mice, that oxybutynin binds more to receptors in the submaxillary gland than the bladder may be due to various factors present in in vivo experiments that could affect the concentration of drug reaching a tissue. These include a rapid rise of plasma drug concentration occurring after oral oxybutynin, the amount and rate of drug reaching each tissue depending on the organ blood flow and the formation of the active metabolite (DEOB). In fact, we have recently shown that i.v. injected DEOB, similar to oxybutynin, binds more extensively to muscarinic receptors in the submaxillary gland than in the bladder of rats (Oki et al., 2005) .
It is possible that in our study the doses of solifenacin used exert anticholinergic effects in the bladder. In our preliminary experiments 93.2% of solifenacin bound to plasma protein and the free fractions present in plasma were estimated to be 60.2 nM (0.5 h), 37.1 nM (2 h) and 12.1 nM (6 h) at 62.4 mmol kg À1 , and 93.9 nM (2 h), 54.7 nM (6 h) and 19.2 nM (12 h) at 208 mmol kg
À1
. As the in vitro K i value of this agent in displacing bladder [ 3 H]-NMS binding is 41.9 nM, it is possible that solifenacin at the oral doses used elicits significant blockade of muscarinic receptors in this tissue. In fact, we have shown that solifenacin at oral doses of 2.1-62.4 mmol kg À1 significantly attenuates the carbachol-induced increase in mouse intravesical pressure in a dose-dependent manner (Sato et al., unpublished observations).
In in situ experiments in anaesthetized rats, Ikeda et al. (2002) have shown that intravenous solifenacin is 2 and 6.5 times weaker than oxybutynin at inhibiting carbachol-induced bladder contractions and salivary secretion, respectively, indicating the selectivity of solifenacin for the bladder. Similarly, Ohtake et al. (2004) found that solifenacin had a greater selectivity for the urinary bladder compared to the salivary gland in rats. In the present study, pilocarpine-induced salivary secretion in mice was markedly reduced 0.5-6 h after oral solifenacin (62.4 and 208 mmol kg À1 ), but was completely abolished 0.5 h after oral administration of oxybutynin (76.1 mmol kg À1 ). The rapid cessation of salivary secretion induced by oral oxybutynin did not occur in mice receiving oral solifenacin and the pK B values showed that solifenacin was significantly (5 times) weaker than oxybutynin, at inhibiting pilocarpineinduced salivation. Thus, the intensity and time-course of the inhibitory effects of solifenacin and oxybutynin on salivary secretion after oral administration appear to accord well with those for muscarinic receptor binding in the submaxillary gland.
After oral administration of oxybutynin, similar concentrations of DEOB as those for oxybutynin were detected in the plasma of mice. The in vitro receptor binding affinity of DEOB in mouse tissues was 3-6 times higher than that of oxybutynin, with the highest affinity (6 times that of oxybutynin) occurring in the submaxillary gland. In man, Waldeck et al. (1997) showed a higher affinity of DEOB for muscarinic receptors in the parotid gland relative to the bladder. These data suggest that DEOB contributes more significantly to the blockade of muscarinic receptors in exocrine gland receptors than oxybutynin under in vivo conditions.
In conclusion, the results from the present study, show that oral solifenacin significantly binds to muscarinic receptors in various tissues of mice, including the bladder, and that this binding is persistent in tissues expressing the M 3 subtype. Further, the inhibitory effect of solifenacin on pilocarpineevoked salivary secretion was significantly weaker but more persistent than that of oxybutynin.
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